Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 765

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 7
Chunk 765
---

and our ability to generate revenues, if any.

59

Our recurring net losses and
negative cash flows from operations raise substantial doubt regarding our ability to continue as a going concern within one year after
the issuance of our consolidated financial statements for the year ended December 31, 2024. Until we can generate sufficient revenue from
the commercialization of our product candidates, we expect to finance our operations through the public or private sale of equity, debt
financings or other capital sources, such as government funding, collaborations, strategic alliances, divestment of non-core assets, or
licensing arrangements with third parties. To date, the Company has relied on equity and debt financing to fund its operations.

Components of Operating Results 

Operating Expenses 

Research and Development

Research and development expense
consists of expenses incurred while performing research and development activities to discover and develop our product candidates. This
includes conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings
for product candidates. We recognize research and development expenses as they are incurred. Our research and development expense primarily
consist of:

    ●
    clinical trial and regulatory-related costs;

    ●
    expenses incurred under agreements with investigative sites and consultants that conduct our clinical trials;

    ●
    manufacturing and testing costs and related supplies and materials; and

    ●
    employee-related expenses, including salaries, benefits, travel and stock-based compensation

The following table summarizes
our research and development expenses by product candidate for the periods indicated (in thousands):

    Year Ended December 31, 

    2024  
    2023 
  
    External Costs 

    DN-TNF – Alzheimer’s disease 
    $23,765  
    $13,817 
  
    INKmune (High Risk MDS/AML & Prostate Cancer) and CORDStrom 
     4,589  
     3,296 
  
    Preclinical and other programs 
     611  
     921 
  
    Accrued research and development rebate 
     (1,823) 
     (3,040)
  
    Total external costs 
     27,142  
     14,994 
  
    Internal Costs 
     6,024  
     5,279 

    $33,166  
    $20,273 

We
typically use our employee resources across our development programs. We track outsourced development costs by